Top Page
Dimerix Limited
(Sydney:DXB)
Dimerix Limited (DXB) vs. iShares MSCI Australia ETF (EWA)
Dimerix Limited Business Overview & Revenue Model
Dimerix Limited Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 5.59M | 1.25M | 583.48K | 36.79K | 6.46M | 4.44M |
| Gross Profit | 5.59M | 1.25M | 583.48K | 36.79K | 6.41M | 4.39M |
| EBITDA | -31.67M | -36.22M | -24.96M | -22.68M | -16.47M | -10.02M |
| Net Income | -13.25M | -13.25M | -17.07M | -13.80M | -10.49M | -6.37M |
Balance Sheet | ||||||
| Total Assets | 91.18M | 91.18M | 32.08M | 17.76M | 16.50M | 9.42M |
| Cash, Cash Equivalents and Short-Term Investments | 68.28M | 68.28M | 22.14M | 7.99M | 9.63M | 5.25M |
| Total Debt | 97.48K | 97.48K | 149.68K | 5.96M | 73.10K | 5.09M |
| Total Liabilities | 77.80M | 77.80M | 13.89M | 11.79M | 2.07M | 7.95M |
| Stockholders Equity | 13.38M | 13.38M | 18.19M | 5.96M | 14.42M | 1.47M |
Cash Flow | ||||||
| Free Cash Flow | 39.03M | 39.03M | -7.02M | -12.73M | -13.45M | -6.47M |
| Operating Cash Flow | 39.05M | 39.05M | -7.00M | -12.73M | -13.44M | -6.46M |
| Investing Cash Flow | -21.01K | -21.01K | -15.80K | -2.30K | -10.61K | 4.38K |
| Financing Cash Flow | 7.42M | 7.42M | 21.17M | 11.07M | 17.69M | 3.83M |
Dimerix Limited Technical Analysis
Dimerix Limited Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
73 Outperform | $543.67M | 14.99 | 15.90% | 0.46% | 7.76% | 1.55% | |
54 Neutral | AU$564.41M | ― | -27.89% | ― | ― | 67.26% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | AU$294.19M | -20.59 | -83.97% | ― | 1271.12% | 36.87% | |
41 Neutral | AU$375.34M | ― | -35.86% | ― | ― | -19.21% | |
41 Neutral | AU$314.20M | -32.31 | -89.70% | ― | 42.05% | -0.84% | |
40 Underperform | AU$106.68M | -13.09 | -47.98% | ― | 700.00% | 26.88% |
Dimerix Limited Corporate Events
Dimerix Limited has announced the issuance of 212,170 fully paid ordinary shares following the cashless exercise of 799,500 unlisted options. This move, which was made without disclosure under Part 6D.2 of the Corporations Act 2001, signifies the company’s adherence to regulatory compliance and may impact its market positioning by potentially increasing liquidity and shareholder value.
The most recent analyst rating on (AU:DXB) stock is a Buy with a A$1.46 price target. To see the full list of analyst forecasts on Dimerix Limited stock, see the AU:DXB Stock Forecast page.
Dimerix Limited has announced the application for quotation of 212,170 ordinary fully paid securities on the Australian Securities Exchange (ASX), under the code DXB. This move is part of an employee incentive scheme, indicating the company’s efforts to motivate and retain talent, which could positively impact its operational capabilities and market positioning.
The most recent analyst rating on (AU:DXB) stock is a Buy with a A$1.46 price target. To see the full list of analyst forecasts on Dimerix Limited stock, see the AU:DXB Stock Forecast page.
Dimerix Limited announced that its CEO, Dr. Nina Webster, will present at the Canaccord Drug & Device Conference 2025, highlighting the status of their Phase 3 global clinical trial for FSGS kidney disease and commercial partnering efforts. This presentation underscores Dimerix’s commitment to advancing DMX-200, a promising treatment for FSGS, a rare kidney disorder with limited treatment options, potentially enhancing their market positioning and offering hope for patients with unmet medical needs.
The most recent analyst rating on (AU:DXB) stock is a Buy with a A$1.46 price target. To see the full list of analyst forecasts on Dimerix Limited stock, see the AU:DXB Stock Forecast page.
Dimerix Limited has announced the details for its 2025 Annual General Meeting (AGM), which will be held in person at its office in Fitzroy, Victoria. The company has made available the Notice of Meeting and Proxy Form online, emphasizing the importance of shareholder engagement and participation in the upcoming meeting. This announcement reflects Dimerix’s commitment to transparency and effective communication with its stakeholders, as it continues to advance its clinical programs and strengthen its position in the biopharmaceutical industry.
The most recent analyst rating on (AU:DXB) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Dimerix Limited stock, see the AU:DXB Stock Forecast page.
Dimerix Limited announced the successful completion of a data analysis by the PARASOL collaboration, which supports the use of proteinuria endpoints in their ACTION3 study for potential marketing approval in the US. The analysis observed a potential relationship between proteinuria at 12 months and the risk of kidney failure, which will be discussed with the FDA for possible accelerated approval pathways. This development could significantly impact Dimerix’s operations and industry positioning by potentially expediting the approval process for their kidney disease treatment, thereby benefiting stakeholders.
The most recent analyst rating on (AU:DXB) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Dimerix Limited stock, see the AU:DXB Stock Forecast page.
Dimerix Limited announced that its lead asset, DMX-200, has received Orphan Drug Designation in Japan for treating Focal Segmental Glomerulosclerosis (FSGS), a rare kidney disease. This designation provides significant benefits such as financial incentives, regulatory assistance, and market exclusivity, enhancing the commercial potential of DMX-200. The Phase 3 clinical trial, ACTION3, is currently recruiting in Japan, and Dimerix’s commercial partner, FUSO Pharmaceutical Industries, has exclusive rights to develop and commercialize DMX-200 in Japan. The designation marks a major milestone for Dimerix’s global strategy to provide new treatment options for FSGS patients.
The most recent analyst rating on (AU:DXB) stock is a Buy with a A$1.46 price target. To see the full list of analyst forecasts on Dimerix Limited stock, see the AU:DXB Stock Forecast page.
Dimerix Limited has announced that its Annual General Meeting (AGM) will take place on 18 November 2025 at its office in Fitzroy, Victoria. The meeting will include an update from CEO Dr. Nina Webster, and the deadline for director nominations is set for 30 September 2025. This announcement is significant for stakeholders as it provides an opportunity for shareholders to receive updates on the company’s progress and strategic direction, particularly regarding its Phase 3 clinical developments.
The most recent analyst rating on (AU:DXB) stock is a Buy with a A$1.46 price target. To see the full list of analyst forecasts on Dimerix Limited stock, see the AU:DXB Stock Forecast page.
Dimerix Limited, a biotechnology company, is working on innovative therapies to tackle inflammatory kidney diseases with unmet clinical needs. The company’s recent announcement highlights its ongoing efforts in drug development, emphasizing the challenges and risks associated with regulatory processes, clinical trials, and patent protection. This development could significantly impact the company’s operations and industry positioning, offering potential benefits to stakeholders if successful.
The most recent analyst rating on (AU:DXB) stock is a Buy with a A$1.58 price target. To see the full list of analyst forecasts on Dimerix Limited stock, see the AU:DXB Stock Forecast page.
Dimerix Limited reported a significant increase in revenues from ordinary activities, up 914% to $5.9 million for the year ended June 30, 2025. Despite this revenue growth, the company recorded a loss of $13.25 million, which is a 22% improvement from the previous year’s loss. The company did not declare any dividends during this period. This financial performance reflects Dimerix’s ongoing investment in its product development pipeline, which is crucial for its long-term strategic positioning in the biotechnology sector.
The most recent analyst rating on (AU:DXB) stock is a Buy with a A$1.58 price target. To see the full list of analyst forecasts on Dimerix Limited stock, see the AU:DXB Stock Forecast page.
Dimerix Limited has released an updated investor presentation and video detailing the progress of its Phase 3 clinical asset, DMX-200, for treating Focal Segmental Glomerulosclerosis (FSGS), a rare kidney disease with no approved therapies. The presentation outlines the clinical trial design, potential market opportunities, and strategic partnerships valued at up to $1.4 billion, which bolster the company’s financial position and operational capabilities. The collaboration with the FDA-led Project PARASOL highlights efforts to establish appropriate clinical trial endpoints and explore accelerated approval pathways in the US, emphasizing the potential impact of DMX-200 on the market and patient care.
The most recent analyst rating on (AU:DXB) stock is a Buy with a A$1.33 price target. To see the full list of analyst forecasts on Dimerix Limited stock, see the AU:DXB Stock Forecast page.
Dimerix Limited has announced the issuance of 41,710 fully paid ordinary shares following the cashless exercise of 250,000 unlisted options. This strategic move, compliant with relevant sections of the Corporations Act, reflects the company’s ongoing efforts to optimize its capital structure and enhance shareholder value.
The most recent analyst rating on (AU:DXB) stock is a Buy with a A$1.33 price target. To see the full list of analyst forecasts on Dimerix Limited stock, see the AU:DXB Stock Forecast page.
Dimerix Limited has announced the application for quotation of 41,710 ordinary fully paid securities on the Australian Securities Exchange (ASX). This move is part of an employee incentive scheme, indicating a strategic effort to motivate and retain talent within the company, which could positively impact its operational capabilities and market positioning.
The most recent analyst rating on (AU:DXB) stock is a Buy with a A$1.33 price target. To see the full list of analyst forecasts on Dimerix Limited stock, see the AU:DXB Stock Forecast page.
Dimerix Limited announced that its CEO, Dr. Nina Webster, presented at the Bioshares Biotech Summit, highlighting the next steps for the ACTION3 Phase 3 clinical trial and the rationale for commercial partnerships. This presentation underscores Dimerix’s strategic focus on advancing its clinical programs and engaging with equity capital markets, potentially enhancing its industry positioning and stakeholder engagement.
The most recent analyst rating on (AU:DXB) stock is a Buy with a A$1.33 price target. To see the full list of analyst forecasts on Dimerix Limited stock, see the AU:DXB Stock Forecast page.